Abstract
Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Current Psychopharmacology
Title:Antipsychotics Management in Addictive Disorders
Volume: 2
Author(s): Pierre Alexis Geoffroy, Benjamin Rolland, Vincent Laprevote and Olivier Cottencin
Affiliation:
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Abstract: Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Export Options
About this article
Cite this article as:
Geoffroy Alexis Pierre, Rolland Benjamin, Laprevote Vincent and Cottencin Olivier, Antipsychotics Management in Addictive Disorders, Current Psychopharmacology 2013; 2 (3) . https://dx.doi.org/10.2174/221155601130200006
DOI https://dx.doi.org/10.2174/221155601130200006 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine The Emerging Role of Atrial Natriuretic Peptide in Psychiatry
Current Medicinal Chemistry NPalmitoylDeep-PseAAC: A Predictor of N-Palmitoylation Sites in Proteins Using Deep Representations of Proteins and PseAAC via Modified 5-Steps Rule
Current Bioinformatics Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Meet Our Editorial Board Member:
Combinatorial Chemistry & High Throughput Screening Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) The Inhibitory Effect of Panax Ginseng Extract on Amyloid-like Fibril Formation of Trypsin in Aqueous Ethanol
Protein & Peptide Letters Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Current Alzheimer Research α-Synuclein- and MPTP-Generated Rodent Models of Parkinsons Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach
CNS & Neurological Disorders - Drug Targets Exposure of Aggregation-Prone Segments is the Requirement for Amyloid Fibril Formation
Current Protein & Peptide Science Probiotic Supplementation in Patients with Alzheimer’s Dementia - An Explorative Intervention Study
Current Alzheimer Research Image Based Brain Segmentation: From Multi-Atlas Fusion to Deep Learning
Current Medical Imaging